Compare Novo Nordisk A/S (NVO) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.69. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals.
| NVO | VNQI | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | — |
52-Week High | $71.70 | $50.76 |
52-Week Low | $35.29 | $43.26 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.69, showing minimal daily movement with a slight 0.07% decline. The technical picture remains bearish with moving averages signaling caution, though oscillators are neutral. The fund provides international real estate diversification with 682 holdings across 30+ countries, featuring a low 0.12% expense ratio and attractive 4.6% dividend yield. Recent analysis highlights its role as a cost-effective diversifier for U.S.-focused real estate portfolios.
VNQI offers exposure to recovering global real estate markets with transaction volumes expected to grow over 10% in 2026. The fund trades at attractive valuations (0.9x P/B, 11.9x P/E) but faces headwinds from international market volatility and currency risks. While providing yield advantages over domestic peers, its total returns have lagged, making it suitable for investors seeking international diversification and income rather than growth leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
